Brief: Matinas Biopharma Announces Collaboration With National Institute Of Allergy And Infectious Diseases To Evaluate Oral Formulations Of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
07/12/2020 11:42
Dec 7 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES COLLABORATION WITH THE
NATIONAL
INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES TO EVALUATE ORAL
FORMULATIONS OF GILEAD’S ANTIVIRAL REMDESIVIR UTILIZING MATINAS’
LNC PLATFORM DELIVERY TECHNOLOGY
* MATINAS BIOPHARMA - ANY PRODUCT GENERATED AS A PART OF
EFFORTS
BY MATINAS AND NIAID WOULD REQUIRE A LICENSE FROM GILEAD FOR USE
OF REMDESIVIR
* MATINAS BIOPHARMA - ANY PRODUCT GENERATED AS A PART OF
EFFORTS
BY MATINAS AND NIAID WOULD REQUIRE LICENSE FROM MATINAS FOR USE
OF LNC FORMULATION
Source text for Eikon: ID:nGNX35q7Tm
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing